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Fungi are generally benign members of the human mucosal flora or live as saprophytes
in the environment. However, they can become pathogenic, leading to invasive and
life threatening infections in vulnerable patients. These invasive fungal infections are
regarded as a major public health problem on a similar scale to tuberculosis or malaria.
Current treatment for these infections is based on only four available drug classes.
This limited therapeutic arsenal and the emergence of drug-resistant strains are a
matter of concern due to the growing number of patients to be treated, and new
therapeutic strategies are urgently needed. Adaptation of fungi to drug pressure involves
transcriptional regulation, in which chromatin dynamics and histone modifications play
a major role. Histone deacetylases (HDACs) remove acetyl groups from histones and
actively participate in controlling stress responses. HDAC inhibition has been shown to
limit fungal development, virulence, biofilm formation, and dissemination in the infected
host, while also improving the efficacy of existing antifungal drugs toward Candida spp.
In this article, we review the functional roles of HDACs and the biological effects of HDAC
inhibitors on Candida spp., highlighting the correlations between their pathogenic effects
in vitro and in vivo. We focus on how HDAC inhibitors could be used to treat invasive
candidiasis while also reviewing recent developments in their clinical evaluation.
Keywords: HDAC, chromatin, acetylation, Candida, HDAC inhibitors
Invasive fungal infections have become a major public health problem, with up to two million cases
worldwide each year (Brown et al., 2012). In developed countries, disseminated candidiasis, mostly
caused by the yeasts Candida albicans, C. glabrata, and C. parapsilosis, remains the predominant
threat, with more than 400,000 cases per year (Brown et al., 2012). Antifungal treatments are
currently based on only four classes of drugs: polyenes, principally represented by amphotericin B;
triazoles; echinocandins; and pyrimidines (Denning and Bromley, 2015). The emergence of strains
resistant to this limited arsenal makes the need for novel therapeutic agents urgent (Denning and
Bromley, 2015).
Candida albicans is the predominant cause of invasive candidiasis, and is also the most
extensively studied Candida species. Its great success as a pathogen is linked to its capacity to
survive in the bloodstream, to invade tissues and to effectively adapt to a range of host niches.
One of its key virulence traits is its morphological plasticity; its ability to shift from a yeast form to
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a hyphal form has been clearly linked to virulence (Sudbery,
2011; Gow et al., 2012). Hyphal forms adhere better to mucosal
niches, making it easier to maintain their colonization. This
colonization can lead to epithelial rupture, dissemination of the
pathogen in the bloodstream and ultimately invasion of deep-
seated tissues. Other virulence factors, such as the white-to-
opaque switch, the GUT (Gastrointestinally IndUced Transition)
or gray phenotypes, cell wall plasticity, adherence, and biofilm
formation favor development in the host (Polke et al., 2015).
Candida albicans’ capacity to adapt to various environmental
conditions, including drug pressure, is linked to a complex
interplay of stress-signaling responses (Fuchs and Mylonakis,
2009; Shor and Perlin, 2015). This signaling alters the
transcription program to adapt the production of proteins,
causing the emergence of the biological state that will be
the most beneficial for yeast survival and development.
Transcriptional regulation requires transcription factors to
bind their DNA template and subsequently recruit dedicated
machinery for transcription repression or activation. Classical
histone modifications, such as acetylation, methylation, and
phosphorylation have been shown to play a role in regulating
stress responses, antifungal tolerance and virulence in C. albicans
and C. glabrata (Liu et al., 2005; Rai et al., 2012; Stevenson and
Liu, 2013; Kim et al., 2015; Tscherner et al., 2015). In particular,
reversible acetylation by various histone acetyltransferases
(HATs) and histone deacetylases (HDACs, also known as
lysine deacetylases or KDACs) is crucial to chromatin-mediated
transcriptional regulation. Recent studies have suggested that
inhibiting fungal HDACs may have beneficial and synergistic
effects, reducing the virulence and growth of Candida spp.,
while also decreasing their tolerance and resistance to existing
antifungal drugs (Al-Dhaheri and Douglas, 2010; Wurtele
et al., 2010; Stevenson and Liu, 2011; Hnisz et al., 2012;
Lu et al., 2012; Nobile et al., 2014; Rajasekharan et al.,
2015; Li et al., 2015; Pfaller et al., 2015; Zhang and Xu,
2015).
In this review, we briefly summarize the advances made
in the characterization of HDACs in Candida spp. We have
also correlated the functional roles of HDACs and the in vitro
biological properties of HDAC inhibitors on Candida spp.,
mostly C. albicans, with their in vivo effects and discussed the
potential for development of new antifungal compounds.
HDACs IN Candida SPECIES
To date, a total of 11 HDACs have been identified in C. albicans
and C. glabrata (Figure 1; Tables 1 and 2). These two species
represent the major proportion of the fungal infections clinically
observed and regroup most of the molecular information
accumulated on fungal HDACs. Three main classes of HDACs
have been originally described in C. albicans based on the key
S. cerevisiae enzymes (Trojer et al., 2003; Kim et al., 2015). The
key enzyme for Class I HDACs is Rpd3, for Class II it is Hda1,
and for Class III it is Sir2, a sirtuin. This family of enzymes uses a
specific enzymatic chemistry based on the cofactor nicotinamide
adenine dinucleotide (NAD).
Class I HDACs: Rpd31, Rpd32, Hos1, and
Hos2
Interestingly, C. albicans possesses two genes which are potential
orthologs of S. cerevisiae’s RPD3. These genes are now designated
as RPD31 and RPD32. The current annotation of these genes
has given rise to some confusion, with discrepancies between
the original publication (Srikantha et al., 2001) and the current
annotation in the Candida Genome Database (CGD; Assembly
22, version s06-m01-r01). Table 1 presents updated information
on the gene and protein accession numbers. Hos1 was first
identified and cloned 15 years ago inC. albicans, but its functional
role has remained elusive (Srikantha et al., 2001). Hos2 was
initially described in the CGD as a Class III enzyme with sirtuin
activity (Karthikeyan et al., 2013), but it is now presented as a
member of the class I family (Kim et al., 2015). In vitro analysis
of the enzymatic activity of recombinant Hos2 showed it to
be inactive on acetylated histones but capable of deacetylating
acetylated tubulin (Karthikeyan et al., 2013). These findings
remain to be confirmed in vivo.
Class II HDACs: Hda1 and Hos3
Hda1 was identified in 2001 and was shown to play an important
role in hyphal development (see below). Hos3 was also described
in 2001, but its function has yet to be studied in detail in Candida
spp. (Srikantha et al., 2001).
Class III HDACs: Sir2 and Hst Proteins
The sirtuin family, a group of NAD+-dependent HDACs, is
conserved between some yeasts and humans. Sirtuins were first
characterized in Candida spp. in 1999, with the identification
and cloning of the SIR2 gene in C. albicans (Pérez-Martín et al.,
1999). Sir2 deacetylates histones, specifically lysine 16 on histone
H4, it is also important for silencing at telomeres and ribosomal
genomic regions (Freire-Benéitez et al., 2016). Interestingly,
SIR2 is not present in all Candida spp. Thus, for example in
C. lusitaniae, no Sir functionality for heterochromatic silencing in
subtelomeric and pericentric regions has been detected, while in
other species such as C. albicans or C. glabrata, an ancestral gene
was duplicated to generate HST1 and SIR2 (Froyd et al., 2013;
Kapoor et al., 2015).
Hst are also members of the sirtuin family; Hst1 is a
component of the Set3 HDAC complex, while Hst3 is involved in
nucleosome assembly. With the HAT Rtt109, Hst3 dynamically
controls the level of lysine 56 acetylation on histone H3 (Rundlett
et al., 1996; Wurtele et al., 2010).
Other HDACs: Set3
Set3 is an NAD+-dependent HDAC, which, in S. cerevisiae,
forms a 7-subunit complex (Set3C) containing HDAC and non-
HDAC proteins in C. albicans (Hnisz et al., 2010, p. 2). Four
of these proteins, Set3, Hos2, Snt1 and Sif2, constitute the core
complex and are essential for Set3C assembly, while three others
(Hos4, Hst1, and Cpr1) are peripheral. Set3, Hos2, and Hst1 have
HDAC activity. In addition, the PhD finger domain of Set3 binds
methylated H3K4 and recruits the Set3C complex to chromatin
in S. cerevisiae (Kim et al., 2012). This complex is conserved
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FIGURE 1 | Phylogenetic trees representing HDACs in S. cerevisiae, C. albicans, and C. glabrata. Percent identities matrices between these HDACs are
presented in Supplementary Table S1.
in C. albicans, where it is important for morphogenesis (Nobile
et al., 2014).
FUNCTIONAL ROLES OF HDACs IN
Candida albicans
HDACs and Yeast-to-Hyphae Transition
Candida albicans exists in various morphological forms: an
ovoid-shaped yeast phase is commonly found on mucosal
and skin surfaces, where it is well tolerated by the immune
system; hyphal forms possess a long tube-like extension to
provide increased potential invasiveness. Both forms contribute
to disseminated infections, but the ability to reversibly switch
from one form to the other has been directly linked to
virulence. The yeast-to-hyphae transition is controlled by
various pathways which were recently reviewed (Sudbery,
2011).
The functional role of many HDACs has been linked to
the yeast-to-hyphae transition (Figure 2A). First, Hda1 was
reported to be important for a specific chromatin state during
hyphal elongation and maintenance (Lu et al., 2011); C. albicans
strains deleted for the HDA1 gene are unable to maintain hyphal
development. Hda1 is recruited by the transcription factor Brg1
and establishes a chromatin state which is not permissive to Nrg1
repressor binding. Thus, Nrg1 is unable to bind the promoter
regions of hypha-specific genes and prevent their expression
(Lu et al., 2011, 2012). And in the absence of Nrg1, Hda1
also maintains a nucleosomal structure compatible with the
expression of the hyphal genes.
The yeast-to-hyphae transition is also controlled by Rpd31,
which acts both as a repressor and an activator (Figure 2A).
In yeast cells, Rpd31 is repressing the expression of hyphal-
specific genes such as HWP1 and ECE1 and under non-
hyphae-inducing conditions, these genes are activated when
RPD31 or SSN6 are deleted (Lee et al., 2015). However,
under filament-inducing conditions, the Rpd31-Ssn6 complex
TABLE 1 | Gene and protein accession numbers for HDACs expressed in
C. albicans.
Classes Name Gene name Protein ID Reference
I Rpd3 type Rpd31 CR_02760C Q5A209 Srikantha et al., 2001
Rpd32 C3_07000W Q5ADP0 Hnisz et al., 2009
Hos1 C4_06010C Q59Q78 Srikantha et al., 2001
Hos2 C3_00780W Q5A839
Q5A7T9
Srikantha et al., 2001
II Hda1 type Hda1 CR_02050C Q5A960 Klar et al., 2001;
Srikantha et al., 2001;
Hnisz et al., 2009;
Zacchi et al., 2010
Hos3 C4_02300W Q5AF34 Srikantha et al., 2001
III Sirtuin Sir2 C2_01330C O59923 Klar et al., 2001;
Maglott et al., 2007;
Fu et al., 2008; Nobile
et al., 2012
Hst1 C1_09050W Q5AQ47 Maglott et al., 2007;
Hnisz et al., 2009
Hst2 CR_01800C Q5A985 Maglott et al., 2007;
Hnisz et al., 2009;
Nobile et al., 2012
Hst3 C5_01340W Q5A1W9 Enjalbert et al., 2006;
Maglott et al., 2007;
Wurtele et al., 2010;
Singh et al., 2011;
Stevenson and Liu,
2011
Fungi only Set3 C1_14140C_A Q59ZX1 Uhl et al., 2003;
Maglott et al., 2007;
Hnisz et al., 2009,
2010
promotes filamentous elongation by triggering the expression
of the master regulator UME6, a key factor in hyphal
differentiation (Lee et al., 2015). Finally, the Set3C complex
has been identified as a repressor of the yeast-to-hyphae
transition (Figure 2A). In hyphae-inducing conditions in vitro,
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TABLE 2 | Gene and protein accession numbers for HDACs expressed in
C. glabrata.
Classes Name Gene name Protein ID Reference
I Rpd3 type Rpd3 CAGL0B01441g Q6FXA7 This study
Hos1 CAGL0D01430g Q6FWB7 Dujon et al., 2004
Hos2 CAGL0A03322g Q6FY81 This study
II Hda1 type Hda1 CAGL0J03454g Q6FPJ0 This study
Hos3 CAGL0J06974g Q6FP35 Dujon et al., 2004
III Sirtuin Sir2 CAGL0C05357g Q6FWI7 Dujon et al., 2004
Hst1 CAGL0K01463g Q6FNA6 This study
Hst2 CAGL0L08668g Q6FKU1 Dujon et al., 2004;
Domergue et al., 2005
Hst3 CAGL0H08239g Q6FRI7 Dujon et al., 2004
Hst4 CAGL0F05621g Q6FU79 This study
Fungi only Set3 CAGL0G04499g Q6FT89 This study
set3-, and hos2-null mutant strains had hyperfilamentous
phenotypes (Hnisz et al., 2010, p. 3). The same authors later
showed that the set3 mutant induces transient upregulation
of EFG1 and NRG1, and downregulation of other hyphal
associated genes, such as BRG1 and TEC1 (Hnisz et al.,
2012).
HDACs and the White-to-Opaque
Transition
Candida albicans colonies are typically white and smooth, but
under some specific conditions, such as genetic conversion at
the mating-type locus, a morphological white-to-opaque switch
can occur. White cells have been showed to be more virulent in
murine models (Kvaal et al., 1997). In human systemic infections,
white cells are more likely to be isolated, whereas opaque
cells may be better adapted to colonization (Morschhäuser,
2010).
The white-to-opaque transition involves a set of transcription
factors responsible for the control of genes specific to white and
opaque cells (Hernday et al., 2013). These factors are naturally
linked to the transcription and chromatin machinery. Strains
deleted for either HDA1 or RPD31 showed an enhanced ability
to switch from the white to the opaque state, while only the
rpd311 mutant displayed increased reverse opaque-to-white
switch (Figure 2B). Thus, Hda1 selectively represses the white-
to-opaque switch and Rpd31 suppresses the transition in both
directions (Klar et al., 2001; Srikantha et al., 2001).
The sirtuins Hst3 and Sir2 were identified as switch repressors,
whereas Set3C HDACs (Set3 and Hos2) were recognized as
key activators of the white-to-opaque switch (Figure 1) (Pérez-
Martín et al., 1999; Hnisz et al., 2009; Stevenson and Liu, 2011).
HDACs and Biofilm Formation
Candida albicans can form biofilms – multicellular structures
of mixed communities of microorganisms containing yeast
and hyphal forms surrounded by a self-produced extracellular
matrix – which commonly develop on implanted medical devices,
such as intravascular catheters or prostheses, as well as on
mucosal surfaces. Biofilms create secondary infectious foci in
hematogenous disseminated candidiasis through the release of
yeast cells into the bloodstream. They are also an important
source of antifungal resistance because the extracellular matrix
hinders drug diffusion (Taff et al., 2013; Perlin et al., 2015).
Set3C HDACs have been shown to be important for the
development of biofilms (Nobile et al., 2014). Thus, deletion
of SET3 and HOS2 decreases biofilm formation and biomass,
and these mutants seem to be more resistant to mechanical
shearing and yeast dispersion in vivo (Nobile et al., 2014). The
Set3C complex binds to five of the six biofilm master regulators,
namely NRG1, BRG1, TEC1, NDT80, and ROB1. Notably, Nrg1,
which is transiently repressed by Set3C during filamentation, is
involved in the regulation of cellular dispersion (Uppuluri et al.,
2010).
Role of HDACs in Virulence In vivo
Several studies have investigated the role of HDACs in C. albicans
virulence through in vivo experiments, mostly assessing survival
rates after systemic injection of wild-type and mutant strains.
The RPD31 deletion induced filamentation defects and
attenuated virulence when injected into mice (Srikantha et al.,
2001; Lee et al., 2015). These results are consistent with the
hyphae-inducing conditions found in animal models. Likewise,
the set3 mutant displayed a hyperfilamentous phenotype in vitro.
This phenotype was confirmed in vivo in mouse kidneys, but,
surprisingly, it was associated with attenuated virulence (Hnisz
et al., 2010) (Figure 2C). This attenuated virulence could be
linked to the Set3C-mediated transcription regulation which
includes transient downregulation of EFG1 and NRG1 and
induction of BRG1 and TEC1 (Hnisz et al., 2012). In addition,
Hst3 deletion leads to increased H3K56 acetylation, decreased
cell viability with abnormal filamentous growth and genomic
instability. In vivo, this deletion attenuates the virulence of
C. albicans in mice models (Wurtele et al., 2010).
HDACs and Antifungal Resistance
Histone acetylation dynamics and HDACs have been shown to
be involved in the development of resistance to antifungal drugs.
Notably, Li et al. (2015) showed that the expression of HDA1
and RPD3 was increased during acquisition of azole resistance,
but decreased once resistance had been established. Hda1 and
Rpd3 control the acetylation of Hsp90, a protein involved in
the development of drug resistance in various fungi (Cowen and
Lindquist, 2005; Robbins et al., 2012). Inactivation of HDACs
in C. albicans phenocopies the genetic and pharmacological
inhibition of Hsp90, restoring azole susceptibility by blocking the
Hsp90-dependent response involved in azole resistance (Cowen
and Lindquist, 2005).
Some authors initially hypothesized that this effect was
achieved because HDACs directly influenced the expression of
eﬄux transporter genes involved in azole resistance. However,
recent studies suggest that the deletion of HDACs or the use
of HDAC inhibitors could decrease the expression of eﬄux
transporters as a part of a general decrease of histone acetylation
and its consequence on transcription regulation (Li et al., 2015).
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FIGURE 2 | HDACs and morphogenesis in C. albicans. Phenotypic effect of different HDACs during filamentation (A) and the white to opaque transition (B),
(C) HDACs regulate the expression of key transcription factors of regulatory circuits, which regulate the gene expression program during filamentation and the
formation of biofilms. HDAC inhibition deregulates the transcription regulatory circuit, generating a hyperfilamentation phenotype and a loss of virulence in vivo.
Similarly, upon treatment with HDAC inhibitors, biofilms are more robust but have a decreased yeast dispersion and a loss of virulence in vivo.
FUNCTIONAL ROLES OF HDACs IN
Candida glabrata
In the species distribution of invasive candidiasis, C. glabrata
ranks second after C. albicans (Brown et al., 2012). Chromatin
remodeling and sirtuin-family HDACs are required for
C. glabrata to adapt to stressful conditions such as survival
inside phagocytes, adhesion and maintenance of colonization, or
multidrug resistance (Rai et al., 2012; Orta-Zavalza et al., 2013;
De Las Peñas et al., 2015).
Sir2 is important for the regulation of cell adhesion; its absence
reduces silencing and many subtelomeric adhesin-encoding EPA
genes are derepressed (De Las Peñas et al., 2015). Hst1 in
C. glabrata is recruited by the transcription factor Sum1 and
contributes to the repression of PDR1 and CDR1, which regulate
the expression of eﬄux pumps. Thus, when Hst1 is deleted,
these genes are upregulated and azole resistance is enhanced
(Orta-Zavalza et al., 2013).
EFFECTS OF HDAC INHIBITORS ON
Candida spp. IN VITRO
Inhibitors of mammalian HDAC enzymes were first developed
nearly 35 years ago. As soon as the first molecules were
identified, several pioneer studies analyzed their effects on yeast
HDACs.
Non-selective Inhibitors of Class I and II
HDACs
Trichostatin A (TSA) is a well-known HDAC inhibitor. It was
first isolated from a culture broth of Streptomyces platensis and
was initially presented as a fungistatic drug inhibiting growth
of Trichophyton and Aspergillus (Tsuji et al., 1976). Rapidly,
however, it was shown to act on the differentiation of mammalian
cells and to inhibit their HDACs (Yoshida et al., 1987, 1990).
Ten years later, TSA was tested on pathogenic yeasts, including
C. albicans where it induced a dramatic increase in white-to-
opaque transition (Klar et al., 2001). This phenotype is fully
compatible with Hda1 and/or Rpd31 inhibition (see above, Klar
et al., 2001; Srikantha et al., 2001). TSA was also shown to trigger
the yeast-to-hyphae conversion of C. albicans through inhibition
of Set3C HDACs (Hnisz et al., 2010). Finally, the deletion of Hos2,
a Set3C subunit, but none of the other HDACs, phenocopies the
TSA induced yeast-to-hyphae transition (Hnisz et al., 2010). No
in vitro assessment of TSA on Candida HDACs has been yet
reported but TSA is active on purified Rpd3, Hda1 and Hos3
in S. cerevisiae (Carmen et al., 1999). Therefore, the phenotypes
observed in Candida spp. are likely to be mediated by a direct
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inhibition of the Rpd3, Hda1, and a Hos2 enzyme as a TSA
treatment phenocopies the deletion of these HDACs.
Sodium butyrate is another well-known HDAC inhibitor. In
1978, this fatty acid was shown to inhibit mammalian HDACs.
In 2002, it was tested in C. albicans with other HDAC inhibitors
(Candido et al., 1978; Smith and Edlind, 2002). Sodium butyrate
alone was shown to have minimal effects on growth, heat
sensitivity, and germ tube formation in C. albicans (Smith and
Edlind, 2002), although some reports suggested that it inhibited
growth and biofilm formation in C. albicans, C. parapsilosis, and
Cryptococcus neoformans, while also enhancing the functions of
macrophages in vitro (Candido et al., 1978). Whether its effect on
HDAC enzymes is direct or not remain to be determined.
Some uracil-based compounds have been identified, among
which suberoylanilide hydroxamic acid (SAHA), also known as
vorinostat. This compound is currently licensed for clinical use
for the treatment of cancer. When tested against C. albicans
strains, it displayed relatively low antifungal activity (Mai
et al., 2007), although another study showed that the same
concentration could reduce the pathogenicity of C. albicans by
decreasing its adherence to cultured human cells by 90%, and
significantly inhibiting serum-induced germination (Simonetti
et al., 2007). Finally, apicidin, a cyclic tetrapeptide, displays
limited direct antifungal activity against C. albicans (Smith and
Edlind, 2002).
Sirtuin Inhibitors
Nicotinamide is a vitamin and precursor of NAD+ and a well-
described inhibitor of Class III HDACs, including Sir2 (Landry
et al., 2000; Bitterman et al., 2002; Sanders et al., 2007). It
was shown to have broad antifungal activity against several
pathogenic Candida and Aspergillus species. In particular, the
addition of nicotinamide to wild-type C. albicans cells led to
morphological alterations and strong growth inhibition in vitro,
these effects are thought to be mediated through inhibition of
H3K56 deacetylation (Wurtele et al., 2010).
Thus, the in vitro effects of these non-selective HDAC
inhibitors used alone were only studied in C. albicans and results
were somewhat conflicting. Further studies including C. glabrata
will be needed.
Selective HDAC Inhibitors
In addition to the pan-HDACs inhibitors, such as TSA and
SAHA, a fungal-specific Hos2 inhibitor, MGCD290, has been
developed (Pfaller et al., 2009). No enzymatic data currently
evaluates its effect on purified Hos2, but in vitro, this compound
alone showed a modest activity against Candida spp., with
minimum inhibitory concentrations (MICs) ranging from 0.5 to
16 µg/mL, depending on the species. However, in combination
with azoles, MGCD290 was active against a broad range of fungi,
including molds such as Aspergillus spp., and was promoted as
the way forward for the development of a new class of clinical
drugs.
More generally, the HDAC enzymatic activity is dependent
of key residues which have been highly conserved through
evolution (Lombardi et al., 2011 and Supplementary Figure S1).
Sequence alignments of class I and class II HDACs from
C. albicans and human reveal that Set3 is the most divergent
enzyme, with <20% of identity with human or other C. albicans
HDACs (Supplementary Figure S1; Supplementary Table S2). The
functional study of this enzyme has demonstrated its importance
for the biology of C. albicans and its virulence in vivo (see section
Functional Roles of HDACs in Candida albicans). Altogether,
Set3 appears to be an exceptional candidate for the development
fungal specific HDAC inhibitors. Alternatively, Hos1, Hos3, and
Hst3 could also constitute new potential targets (Supplementary
Table S2).
A new generation of inhibitors has currently been developed
and targets selectively human HDAC isoforms, such as
HDAC1/2, HDAC3, or HDAC8 (for review, Falkenberg and
Johnstone, 2014). This illustrates that high levels of selectivity
can be reached among human HDACs. Similarly, it is very likely
that specific compounds could probably target specifically fungal
HDACs. Structural studies showed that HDAC8 active site is very
malleable and adapts its conformation when different inhibitors
are bound (Somoza et al., 2004). Future work will hopefully
generate more structural information on fungal HDACs and
provide additional insights to the quest for specific fungal
inhibitors.
THE CLINICAL POTENTIAL OF HDAC
INHIBITION IN Candida INFECTIONS
HDAC Inhibitors Bolster Existing
Antifungal Drugs and Limit the
Emergence of Resistance
When used alone, HDAC inhibitors seem to display only a
modest anti-Candida activity, however, their potential increases
exponentially when they are used in combination with existing
antifungal agents. This activity is observed not only with
planktonic cells but also with biofilms.
Thus, HDAC inhibitors can significantly enhance azole
activity in vitro (Smith and Edlind, 2002; Mai et al., 2007; Li
et al., 2015). Combination of TSA with fluconazole, itraconazole,
or voriconazole significantly reduced trailing growth (the
phenotypic expression of drug-tolerance) and/or the azole MICs,
in C. albicans, C. parapsilosis, and C. tropicalis (Smith and
Edlind, 2002; Mai et al., 2007). Similar effects were observed in
C. albicans when SAHA or other hydroxamate-based inhibitors
were used in combination with fluconazole. These observations
are consistent with the increased azole susceptibility of the
HDA1 or RPD3 mutants of C. albicans (Mai et al., 2007;
Zhang and Xu, 2015). MGCD290 also potentiates the activity
of triazoles against Candida spp. in vitro (Pfaller et al., 2009,
2015). This synergy between HDAC inhibitors and antifungals
is not limited to azoles, and TSA was shown to enhance the
activity of other antifungal agents acting on membrane synthesis,
including terbinafine, although it had no effect on the activities of
amphotericin B and 5-fluorocytosine (Smith and Edlind, 2002).
MGCD290 was also found to potentiate the echinocandins,
although this synergistic effect was less pronounced than the
effect with azoles (Pfaller et al., 2015).
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Apart from its activity against Candida spp., MGCD290
was shown to have a synergistic activity with azoles against
Aspergillus, Rhizopus, Mucor, Fusarium, Scedosporium,
Rhodotorula, and Trichosporon genus (Pfaller et al., 2009).
One of the growing threats in the treatment of invasive
candidiasis is the emergence of multidrug resistance, including
echinocandin resistance, especially in C. glabrata (Maubon et al.,
2014). Synergy between HDAC inhibitors, azoles (especially
fluconazole) and echinocandins was also demonstrated for
the treatment of several resistant strains of C. albicans,
C. glabrata, or C. krusei (Pfaller et al., 2009; Li et al., 2015,
p. 3). In vitro, MGCD290 also decreased the echinocandin-
resistance of C. glabrata, C. albicans, and C. krusei isolates.
Moreover, in most azole- or echinocandin-resistant strains,
combination with a HDAC inhibitor led to a shift from
resistance to greater susceptibility (Pfaller et al., 2015). Similarly,
several echinocandin- or azole-resistant C. albicans isolates
were as sensitive to nicotinamide as susceptible strains upon
combined treatment with a HDAC inhibitor (Wurtele et al.,
2010).
Through similar studies, several HDAC inhibitors were shown
to enhance the action of antifungal drugs against fungi present
in biofilms. Thus, Al-Dhaheri and Douglas (2010) showed
that, in the presence of amphotericin B, TSA or apicidin,
sodium butyrate significantly reduced viability of Candida spp.
in biofilms. Similarly, sodium valproate, an organic compound
used as an anticonvulsive agent which has been shown to be
a HDAC inhibitor, used in combination with amphotericin B
showed synergistic antifungal activity on biofilms produced by
C. albicans, C. krusei, and C. parapsilosis (Göttlicher et al.,
2001; Phiel et al., 2001; Al-Dhaheri and Douglas, 2010).
Valproate was the most effective agent against C. krusei,
while butyrate had the greatest impact on C. albicans. Using
a biofilm formation assay, butyrate alone showed antifungal
activity against C. albicans, C. parapsilosis, and C. neoformans
(Hnisz et al., 2012). A combination therapy based on flavonoids
and butyrate also significantly reduced a C. tropicalis biofilm
(Rajasekharan et al., 2015).
Even though they are preliminary, these results with HDAC
inhibitors on biofilms are encouraging. Despite their lack of
specificity, HDAC inhibitors may be used at high concentrations
in the particular context of lock therapy, which involves the
direct application of very high local doses of active drugs to
contaminated catheters. In addition, combinatorial strategies
against biofilms have recently gained interest for the treatment of
Candida infections associated with biofilms on devices (Liu et al.,
2005). Indeed, the disruption of the membrane or the cell wall
by antifungal agents may help promote the uptake of compounds
that are active inside cells.
Use of HDAC Inhibitors in Animal Models
and Clinical Studies
The animal experiments described above confirmed that genetic
inhibition of HDACs produced strains with attenuated virulence
(Figure 2). These experiments are important for functional
studies, but genetic knock-out models are not entirely predictive
of the ability of HDAC inhibitors to cure Candida infection
in vivo.
Indeed, until now, only three HDAC inhibitors have been
tested as therapeutic agents in animal models: the sirtuin
inhibitor nicotinamide (intraperitoneal injection), valproic
acid (intraperitoneal injection) and the Hos2 inhibitor
MGCD290 (oral route). Wurtele et al. (2010) demonstrated
that nicotinamide, mimics the in vitro effects of Hst3 repression,
leading to a loss of virulence in mice. This antifungal effect
requires the presence of the acetyltransferase RTT109 which
acetylates H3K56, suggesting that nicotinamide exerts its
therapeutic effect through inhibition of Hst3p-mediated H3K56
deacetylation. Paradoxically, the intra-peritoneal injection of
high doses of valproic acid in a disseminated mice model of
candidiasis was associated with accelerated (mean time to death:
21.5 days vs. >40 days) and increased mortality (44% vs. 75%,
P = 0.02; Roger et al., 2011). Similarly, MGCD290 was tested
in a murine model of invasive candidiasis in combination
with fluconazole (Besterman J., presented at Interscience
Conference on Antimicrobial Agents and Chemotherapy
IAAC in 2012 in San Francisco, CA, USA). The results of this
study indicated that kidney fungal loads in animals receiving
both MGCD290 and fluconazole were significantly lower
than fungal loads in animals treated with fluconazole alone.
These preliminary results on the use of HDAC inhibitors
in murine models of candidiasis are conflicting, but there
are also major differences between these in vivo models. In
the future, the relevancy of such in vivo experiment will
probably need to be attested to provide clear information
on the therapeutic potential of the tested compounds. Also,
HDAC inhibitors still need to be rigorously tested under
a range of experimental conditions to examine both their
toxicity and antifungal efficacy. Indeed, as several regulatory
and signaling pathways/mechanisms are highly conserved
between fungal and human eukaryotic cells, the use of a non-
selective HDAC inhibitor (acting upstream these pathways)
exposes to the risk of unwanted adverse effects. However,
HDAC inhibitors toxicity does not seem to be a major issue
yet, but the commercially available HDAC is today were only
recently approved. The most common serious adverse events
reported with HDAC inhibitors in cancerology were cytopenia
(thrombocytopenia, anemia, neutropenia, or leukopenia),
pyrexia, infection, sepsis, or cardiac toxicity. Other frequent
adverse reactions are fatigue, nausea and diarrhea (Mottamal
et al., 2015). In a recent phase 2 clinical study, the combination
of oral MGCD290 and fluconazole in patients with moderate
or severe vulvo-vaginal candidiasis, although well tolerated, did
not significantly improve outcome compared with fluconazole
alone (Augenbraun et al., 2013). This result does not support
the therapeutic use of this HDAC inhibitor in this particular
clinical context. Also, there is currently no available data
suggesting that patients treated with HDACs inhibitors are less
susceptible to Candida infection, and more specifically designed
studies, among onco-hematological patients, are needed to
answer this issue. Thus, for now, the clinical utility of HDAC
inhibitors remains to be validated, and further research is more
necessary than ever. The recent and expanding use of the
Frontiers in Microbiology | www.frontiersin.org 7 August 2016 | Volume 7 | Article 1238
fmicb-07-01238 August 3, 2016 Time: 13:40 # 8
Garnaud et al. Inhibiting histone deacetylases in Candida species
Galleria mellonella larvae model, which inter alia allows high-
throughput screening of chemical libraries for the discovery of
new antifungal compounds will probably facilitate the discovery
of more selective and efficient HDAC inhibitors (Lionakis, 2011).
CONCLUSION
The activity of HDAC proteins is essential for the functionality
of chromatin in all eukaryotic cells. In Candida species,
most HDACs contribute to life cycle regulation, morphogenic
plasticity, and biofilm formation; they are also involved in azole-
and echinocandin-resistance. Therefore, their genetic or chemical
inhibition can affect yeast virulence and its capacity to form
biofilms while also enhancing the efficacy of existing antifungal
drugs, even toward resistant strains. Three HDAC inhibitors now
have FDA-approval for clinical use and a dozen compounds
are included in clinical trials for cancer therapy. Obviously,
the development of fungal-specific drugs would have a high
clinical impact as they would avoid inhibition of endogenous
host HDACs, therefore probably reducing side effects. These
molecules already represent a great potential to create new
antifungal treatments, especially given their behavior and how
well they are tolerated in patients. Along with other compounds
targeting innovative machineries (i.e., mitochondrial function,
glycosylphosphatidylinositol biosynthesis, vesicle transport)
which are currently in preclinical development, they may be
incorporated in the antifungal pipeline. However, in vivo tests
should be expanded to include more diverse animal models,
including invertebrates.
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